- LOGIN
- MemberShip
- 2026-04-12 12:52:57
- InterView
- "Will make R&D partnerships, introduce new drugs in Korea"
- by Apr 14, 2022 05:56am
- The China Shanghai-based Antengene has started its activities in earnest in the domestic pharmaceutical market. Marking its start with Xpovio (selinexor), a blood cancer drug that was approved in July last year, the company aims to introduce more new drugs in cancers with high unmet needs. Antengene is an anticancer drug developer that has received investments from global pharmaceutical companies, including BMS. Its founder and CEO Jay Mei, has extensive experience in the field, working at the National Cancer Institute as well as various global pharmaceutical companies including Johnson & Johnson, Novartis, and Celgene, where he led global clinical trial programs. Based on this experience, the CEO founded Antengene, with its key focus of interest in blood cancer. Antengene is one of the few Chinese biotechs that have entered Korea. The company decided to enter Korea as it considers the country an important base in the Asia-Pacific region. The company is also actively engaged in open innovation with bio companies in Korea. It is currently conducting joint research with LegoChem Bio. Through such efforts, Antengene aims to address the unmet medical needs in the Asia-Pacific region, and further expand into a global company. At a virtual interview with Dailypharm on the 14th, CEO Mei (57) said, “We had decided early on that we would need to enter Korea as the country owns a top-class healthcare system, a solid infrastructure for clinical trials, and has a good environment for R&D. We plan to continue expanding our business through joint research in partnership with various Korean companies including Lego ChemBio.” The following is the QA with Antengene’s CEO Jay Mei. Jay Mei, CEO of Antengene-You chose selinexor, an oral anticancer drug you brought in from Karyopharm as the first product for commercialization in Korea. What do you think of selinexor’s vision? =Selinexor was approved as a treatment for multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) treatment by the FDA in July 2019. The drug has been also approved for the two indications in Korea in July last year. Selinexor is an oral selective inhibitor of nuclear export (SINE) that can be used in combination and as monotherapy. We are conducting trials in other blood cancers such as myelofibrosis and acute myeloid leukemia, and are investigating its use in T cell or NK cell-related lymphoma as well. WE plan to continue expanding selinexor’s indication in consideration of its scalability. -What is your key platform technology and pipeline? =Antengene has opted for a two-track approach in which the company seeks growth through partnership-based technology introductions and the development of original pipelines. In addition to Karyopharm, we have made partnership agreements with AstraZeneca, Celgene, and LegoChem Bio. For individual development, our scientists are developing new drugs by investigating new targets. We have a total of 15 progress in progress ranging from non-clinical trials to Phase III trials that are investigating small-molecule drugs, monoclonal antibody therapies, bispecific antibody drugs, ADCs, etc. The trials are underway in Asia and the United States, as well as in Japan and Europe. -What other product do you have in plan to commercialize following selinexor? =We are developing a new drug substance that has the same XP01 inhibiting mechanism of action as selinexor. We are conducting various clinical trials with Karyopharm for the drug, eltanexor (code name ATG016). The target indication is the high-risk group with myelodysplastic syndrome, and a global clinical trial currently in progress is a pivotal clinical trial prepared to be used as the basis for approval reviews. Also, Antengene is developing 6 other new drug candidates for commercialization. First, ‘ATG008' is a new drug candidate that can be used with mTOR inhibitors for the treatment of cervical cancer. The company plans to conduct a global trial if the ongoing clinical trial brings positive results. Also, a clinical trial for a PD-1-based bispecific antibody ‘ATG101' is underway in Australia for patients who cannot see a further effect from existing PD-(L) 1-based immunotherapies. Within the company, ATG101 is considered a unique substance that has the potential to become a ‘best-in-class’ drug. -What is the background on your partnership with LegoChem Bio in Korea? What is your prospect for ADC treatments? = 'ATG022' that we have in our pipeline is an ADC-based treatment that targets claudin-1. Claudin is quite often found in gastric cancer. Antengene is deeply interested in cancers with high prevalence in Asia like gastric cancer and has taken an interest in next-generation ADCs while developing ADCs. In our search for companies with new innovative technology for developing anticancer substances to conjugate with ADC platforms such as linkers or payloads, we came across LegoChem Bio. We believe LegoChem Bio owns a unique technology and strong potential for next-gen ADC development. Both companies have been searching intently for a new candidate substance after signing the partnership. -In addition to Antengene, the global entry of China-based biotechs and their collaboration with big pharmas have been increasing recently. What do you make of this trend? = Despite the remarkable economic development the region had made over the past 30 years, the unmet medical need in the Asian region is still relatively high. Just in the fields of multiple myeloma and lymphoma that Antengene frequently monitors, only half of the drugs approved in the Western countries are approved in Asia. As such, there are still many areas where patient accessibility needs to be increased. Thanks to the development of the economy and healthcare systems, the talent pool is rapidly increasing in Asia as well. As more and more Asian talents with graduate degrees or higher in biology, chemistry, and medicine enter society, there is now an abundant opportunity for Asia-based biopharmaceutical companies to utilize these talents. We believe that these environmental changes played a part in increasing collaboration opportunities for Asian-based biotech companies that have not entered the global market before. The entry of these companies will provide benefit the global patients by developing new drugs based on new technologies and medical knowledge. If European and American companies had fared well in the past 50 or 60 years, I think it is not time for Asian-based companies, including Korea, to play this role now. I think now is the right time to go global. -Many Korean biotechs are also seeking to enter the global market. However, the companies have trouble communicating with the FDA and designing the clinical trial protocols. As a biotech that has commercialized various products, what know-how do you have to share with the Korean companies? =To become a successful bio-company, the company should first own a competitive product or candidate substance. Next is talent. The company needs to recruit a lot of talented people who have global vision and experience, a deep cultural understanding of various countries and can work smoothly as a team with people from other cultures. In the case of our company, we had set the global strategy to expand into Asian countries including Korea, then to go global from the early stages of establishment. So we thought securing the two factors mentioned above was of utmost importance. In particular, as pharmaceuticals are one of the most highly regulated industries, collaboration with regulatory authorities is very important. Also, we have put in a lot of effort to secure a talented workforce that owns such job competencies. Also, finding a reliable local partner can be helpful if you don’t have enough time to set up a solid team in each market. Finding a good partner is as important as securing good talent in-house. This is why we have established partnerships with various companies including Karyopharm, AstraZeneca, Celgene, and LegoChem Bio. -Your Korean branch celebrated its 1st anniversary this year. What other activities do you have in plan for the Korean branch as well as other countries? = Antengene has established subsidiaries in Korea, China, Australia, Singapore, Hong Kong, Taiwan, and the United States, and is aiming to continue expanding in the future in terms of expanding pipelines and talent pools in addition to geographic areas. Currently, Antengene is positioning itself as an 'Asia+' company, and our urgent mission is to meet the unmet medical needs in many Asian countries. Selinexor has been approved in for this purpose in Korea, Australia, Singapore, and China, and is scheduled to be approved in Taiwan and Hong Kong within the year. The second step is to broaden the partnership with the self-developed substances to advance and become a truly global company. I first visited Korea while serving as head of a global clinical program at Novartis, and was also able to broaden my business understanding of Asian counties at Celgene. Building on my experiences, I am determined to drive Antengene's strong growth and expand its businesses in Asia.
- Company
- Somavert for terminal hypertrophy can be prescribed at Big 5
- by Eo, Yun-Ho Apr 14, 2022 05:56am
- Somavert, a new drug for terminal hypertrophy, can be prescribed at a general hospital. According to related industries, Pfizer Korea's Somavert has currently passed DC of the Big 5 higher-level medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, AMC, and Sinchon Severance Hospital. Currently, it can be prescribed in most major hospitals nationwide. Somavert has been listed on the insurance benefit list since September last year, making it easy to access patients. Somavert demonstrated its validity through a SEN-3614 study, a 12-week randomized, double-blind core study in 12 patients with terminal hypertrophy. 112 patients were randomly assigned to the Pegvisomant daily administration group of 10 mg, 15 mg, and 20 mg and placebo administration group, respectively, and the primary validity evaluation variable in the study was a change in serum IGF-I concentration at 12 weeks compared to the baseline. As a result of the study, the median serum IGF-I concentration at 12 weeks compared to the baseline was 4.0±16.8%, 26.7±27.9%, 50.1±26.7%, and 62.5±21.3%, respectively, in the placebo, 10 mg daily, 15 mg, and 20 mg administration groups. The proportion of patients whose serum IFG-I concentration returned to normal to baseline in the placebo-administered group, the Pegvisomant daily 10 mg-administered group, the 15 mg-administered group, and the 20 mg-administered group were 10%, 54%, 81%, and 89%, respectively, indicating that Pegvisomant was significantly higher in all three doses compared to the placebo Somavert did not respond appropriately to surgery and radiation therapy, and was approved in Korea in September last year for the treatment of adult terminal hypertrophy patients with insulin-like growth factor-I (IGF-I) concentration or intolerance due to Somatostatin mitosis treatment.
- Policy
- Omicron recombinant XL mutation found in Korea
- by Lee, Jeong-Hwan Apr 14, 2022 05:56am
- In Korea, the sub-variant XL in which the Omicron COVID-19 mutant virus has been modified (recombined) has been confirmed for the first time. The quarantine authorities predicted that the XL mutation is a subfamily of omicrons, and that caution is necessary, but there will be no excessive concern. The intention is that there is a possibility of natural extinction rather than a dominant mutation after omicron, and various inspection institutions, including the KDCA, can manage and respond during monitoring. On the 12th, the head of the KSLM epidemiological investigation and analysis team said, "In a confirmed case on the 23rd of last month, Omicron recombinant mutation XL was confirmed, and related epidemiological investigations are underway." According to the KSLM, the patient did not have any symptoms, and the COVID-19 vaccination was completed until the third round. XL is a mixture of genes from omicron (BA.1) and stealth omicron (BA.2). It is one of the 17 recombinant mutations identified so far, and no specific characteristics have been reported. According to the World Health Organization (WHO), 66 cases of XL have been confirmed in the UK alone since its first discovery in February. Health and Safety Executive said on the 25th of last month that most recombinant mutations disappear without special diffusion. The KSLM said, "XL recombinant mutations are classified as omicrons by the WHO, so it is not expected that there will be significant changes in characteristics. We will continue to strengthen mutation monitoring because there are no analysis data such as propagation power and severity."
- Policy
- P3T for Roche’s Giredestrant was approved in Korea
- by Lee, Hye-Kyung Apr 14, 2022 05:56am
- A Phase III trial for Roche’s next-generation breast cancer treatment ‘giredestrant’ will be conducted in Korea. The Ministry of Food and Drug Safety approved the company’s application to conduct a randomized, open-label Phase III trial to evaluate the efficacy and safety of ‘giredestrant+ Phesgo’ in comparison to Phesgo in treatment-naïve HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer patients after ‘Phesgo+taxane’ induction therapy. The domestic Phase III trial will be conducted in Seoul St.Mary’s Hospital, Kyungpook National University Chilgok Hospital, the National Cancer Center, Seoul Asan Medical Center, Severance Hospital, and the Samsung Medical Center. Giredestrant is an oral anti-hormonal therapy in the selective estrogen receptor degrader (SERD) class that inhibits the proliferation of cells that bring estrogen to the breast cancer cells. In a Phase II study that administered giredestrant and anastrozole for two weeks in 191 treatment-naïve postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer, giredestrant showed a much greater effect than anastrozole. Also, comparison of the Ki67 protein levels produced when breast cancer cells divide and proliferate as identified through biopsies pre-and post- treatment showed that the mean relative Ki67 reduction from baseline to week 2 was 80% with giredestrant compared to the 67% with anastrozole. Meanwhile, the only SERD class drug to be approved by the US FDA is AstraZeneca’s ‘Faslodex inj. (fulvestrant),’ but the drug is an injection-type rather than an oral type.
- Policy
- Why Galvusmet is priced same as salt-modified and generics
- by Lee, Tak-Sun Apr 13, 2022 06:03am
- Prices of DPP-4 inhibitor Galvus (vildagliptin) and Galvusmet (vildagliptin+metformin) latecomers show that the original Galvus’s price is still set high, but the price of the original Galvusmet (50/500mg) is set at the same level as its salt-modified and generic versions. Also, Galvus’s price had fallen 30% with premium pricing after the introduction of generics, but Galvusmet’s price fell only 25.3%. Why the difference? This is due to the different standards in pricing between single-agent and combination drugs. Galvusmet’s pricing did not follow the general formula. First, combination drugs are not applied the premium pricing formulas. For original single agent drugs, the drugs’ price falls 30% in the first year due to premium pricing, then to 53.55%, same as generics after 1 year. Reimbursement listing status of vildagliptin(50mg)/metformin(500mg) However, original combination drugs are not provided a premium and therefore are discounted and set at 53.55% like its generics at the time of entry. If so, why did Galvusmet’s price drop only 25.3%? It was because its price had been set at a lower level during its initial listing. This is why the drug’s price was set at ₩310, which is a sum of ₩240, the ceiling price of Galvus before premiums, and ₩70, the ceiling price of metformin 500mg. The price of KB Pharma’s salt-modified drug Vildamet tab 50/500mg was also set at ₩310 under the same calculations. Also, United Pharma Korea’s generic version of Galvusmet, ‘Healusmet tab’ was listed at ₩310 like the adjusted price of Galvusmet by satisfying both the direct bioequivalence testing and Regulation on Registration of Drug Substances (DMF) requirements. This is why the original, salt-modified drug and generics were set at the same price upon market entry. On the other hand, the price of generics from companies that were not able to satisfy the direct bioequivalence testing requirements – those from Samjin, Ahn-gook, Ahn-gook New Pharm, and Shinpoong- were set at ₩264. Meanwhile, Hanmi Pharmaceutical’s ‘Vildaglmet 50/500mg,’ which was allowed the same price as KB Pharma’s at ₩310, was voluntarily listed at a lower price of ₩300. Yoon-Hee Choi, Team Head of the Health Insurance Review and Assessment Service’s Drug Pricing Department, said, “No premium is provided for combination drugs, therefore, the price of original combination drugs may be set at the same level as its generics upon entry of generics. However, as Galvusmet’s price had been set at a lower price in its initial listing, the price was not discounted 53.55%, but under a different standard.”
- Company
- “NOAC Eliquis is safe for use in high-risk groups”
- by Apr 13, 2022 06:02am
- The bleeding safety of the novel oral anticoagulant (NOAC) ‘Eliquis (apixaban)’ was reaffirmed through clinical practice guidelines of major academic societies. On the 12th, BMS Korea and Pfizer Korea announced that they have hosted a ‘VMC Master of Masters Webinar’ on the 11th to share the latest advances in preventive therapies for atrial fibrillation and Eliquis’ effect and safety with healthcare professionals in Korea. The webinar was prepared to share the latest advances in stroke prevention for atrial fibrillation patients by sharing the revised clinical practice guidelines from major international societies, and highlighted the stroke prevention effect and bleeding safety of Eliquis. Professor Gregory YH Lip at the University of Liverpool, Professor Jan Steffel at the University of Zurich, and Professor Eue-Keun Choi of the Cardiology Department at Seoul National University Hospital participated as lecturers to introduce the updated guidelines of the ▲European Society of Cardiology (ESC), ▲European Health Rhythm Association (EHRA), and ▲Asia-Pacific Heart Rhythm Society (APHRS). According to Professor Steffel, the EHRA revised its guidelines last year to mention apixaban as one of the preferred NOACs in patients weighing less than 60kg, as it has shown consistent effect and safety compared to VKA in low-weight patients. Apixaban was also mentioned as a NOAC that reduced the risk of major bleeding in high-risk patients such as the elderly and patients with renal impairment. Professor Steffel added, "Special attention is required during anticoagulation therapy, especially in underweight patients, as such treatments are frequently accompanied by conditions that can increase the risk of stroke and bleeding, such as advanced age, cancer, and decreased renal function." Professor Lip introduced an integrated atrial fibrillation management strategy based on ESC guidelines. The integrated management of atrial fibrillation in the ‘Atrial fibrillation Better Care (ABC)’ pathway defines the use of anticoagulant therapy to prevent strokes as the first treatment step. Professor Lip said, “ESC is recommended over non-vitamin K antagonist oral anticoagulants or VTKs in patients with atrial fibrillation that can be administered oral anticoagulants.” Professor Choi highlighted stroke prevention therapy in Asian patients with atrial fibrillation and the use of NOACs in specific patient groups. Professor Choi said, “Patients after atrial fibrillation diagnosis grow older and develop comorbidities such as heart failure, high blood pressure, and diabetes, which continuously increases the risk of strokes. This is why the APRHS guidelines recommend patients to reevaluate their risk of strokes every 4 months.” In particular, Professor Choi focused on the stroke prevention therapies that were newly added for specific patient groups such as those with old age, underweight, liver failure, etc in the updated guidelines. Analysis of major clinical data on 4 types of NOAC (apixaban, dabigatran rivaroxaban, edoxaban) by age showed that apixaban was the only drug to show a reduction in risk of stroke, major bleeding, and intracranial hemorrhages in those between 65 to 74 and over 75 years of age compared to warfarin. On this, Choi said, “The company has steadily accumulated clinical data on various patient groups for Eliquis. The clinical practice guidelines on atrial fibrillation were updated based on real-world data on Eliquis that shows that the drug has consistent effect and safety profile even in specific patients groups, including high-risk group and Asians.”
- Policy
- Korea loses $9 billion a year in exports
- by Lee, Jeong-Hwan Apr 13, 2022 06:02am
- If low- and mid-income countries such as Africa and Central America fail to raise their collective immunity levels sufficiently, it will have a negative impact on the economy, such as a decrease in export profits of high-income countries. This is because countries around the world are linked to each other by trade and investment, and the country that is expected to lose the most is expected to hit the U.S. with $50 billion a year, while Germany is expected to hit $30 billion a year as the second country to lose. Korea is also expected to lose $9 billion a year, and it is analyzed that having an international cooperation system that can fairly inoculate the COVID-19 vaccine will eventually bring economic benefits to rich countries. On the 11th, Kim Joo-kyung, a legislative investigator at the National Assembly's legislative investigation office, made the announcement through the "significance and task of international cooperation to respond to the pandemic of infectious diseases." The main point of the analysis is that in order to minimize economic losses caused by the COVID-19 pandemic, vaccine inequality between countries should be minimized and international cooperation should be strengthened. According to the international statistics site Our World in Data, the rate of COVID-19 vaccine booster shots per 100 people as of the 4th was very low in African continental countries and some Central American countries. Chile (83.3%) and Singapore (70.7%) finished booster shots, and Korea had a high vaccination rate along with 64.6% of Korea, Iceland (67.9%) and Italy (64.9%). Gabon and Cameroon accounted for 0.1% and Ethiopia 0.3%, with most of the African continent countries and Central American countries such as Jamaica (1.1%). The Legislative Research Service pointed out that vaccine nationalism poses health risks such as increasing death and morbidity by continuing the public health crisis situation, while also seriously affecting the global economy. Countries around the world are interconnected by trade and investment, leading to a decrease in economic demand in low- and medium-income countries leading to negative effects such as a decrease in exports to the economies of high-income countries. Kim explained, "If low-income countries fail to raise their collective immunity levels sufficiently, the cumulative economic cost to 30 high-income countries is estimated to be $216 billion in 2022-2023 alone and $258 billion in 2023-2024. Kim added, "The country that is expected to be hit the hardest among the 30 countries will incur $41.3 billion in 2022-2023 and $493 in 2023-2024, and Germany will lose $26.1 billion in 2022-2023 and $31.1 billion in 2023-2024. Korea is expected to suffer economic losses of $8.2 billion from 2022 to 2023 and $9.7 billion from 2023 to 2024, he said. "Quick vaccination is important because potential economic costs arising from the lack of vaccines to poor countries increase over time." Kim stressed that vaccine inequality should be improved through international cooperation. In particular, as Korea has been selected as a "global bio-human resource training hub," it said that it should start seeking international cooperation measures. The global bio-human resources training hub, organized by the World Health Organization (WHO), is a project that provides education and training across the production of vaccines and biopharmaceuticals. Korea will be selected alone and conduct vaccine and biopharmaceutical manufacturing training for 370 global bio-workers from July. Kim said, "The way to solve the COVID-19 pandemic is to improve the current vaccine and vaccinate the most vulnerable people," adding, "To this end, the WHO is trying to supply vaccines fairly through COVAX Facility and transfer vaccine technology to low-income countries." Kim said, "Korea did not have the original technology for COVID-19 vaccines, so it was difficult to supply and demand vaccines in the early days of the pandemic. In response, we have the task of becoming a leading country in the bio-pharmaceutical industry. As Korea has been selected as a global bio-human resource training hub, we need to seek international solidarity and cooperation to contribute to health security around the world."
- Company
- Propecia is sold in a new package
- by Apr 13, 2022 06:02am
- Organon Korea announced on the 11th that it will introduce a new package of the oral male hair loss treatment Propecia (Finasteride). As for the new package, it applied CI of Organon Korea company. Propecia, which has been sold by MSD Korea for more than 20 years since its launch in Korea in 2000, was officially launched and relocated by Organon Korea, which was spun off from MSD in June last year. Organon will consolidate its position as a major product, Propecia, with its new package. Currently, Propecia is on sale in two packaging specifications: 28 tablets and 84 tablets. Organon Korea will supply changed packages for Propecia 84 tablets first in April, and will supply 28 tablets sequentially from May. Depending on the pharmacy, It sells new packages as the old packages are sold depending on the pharmacy. Han Soo-young, head of marketing at Organon Korea's Propecia, said, "This package change means that Propecia is once again announcing its official departure as a major item of Organon, and only the company name has been changed, but the quality of Propecia's production and packaging is the same as before, and Organon Korea Propecia is the No. 1 oral hair loss treatment in Korea, and we will continue to strive for its original value."
- Policy
- Galvusmet latecomers face a price war since launch
- by Lee, Tak-Sun Apr 12, 2022 06:05am
- How price will affect sales of the DPP-4i antidiabetic treatment Galvusmet’s latecomers is gaining attention. Hanmi Pharmaceutical, which had been the first to release a drug to the market, had opted to set its price lower than planned, and the price of the original Galvusmet had also fallen due to the introduction of generics. The price of the generics had also been set accordingly. According to industry sources on the 11th, starting with Hanmi’s Vildaglmet, sales of Galvusmet generics had started in earnest in February, along with sales of KB Pharma’s salt-modified drug in March, all of which as latecomers of Novartis’s Galvusmet (vildagliptin/metformin). The latecomers have been eyeing the Galvusmet market as this fixed-combination drug has been prescribed more than the single-agent Galvus. According to UBIST, Galvus sold ₩8.5 billion and Galvusmet ₩38 billion last year in Korea. Among the latecomers that were newly introduced, only a generic version of the Galvusmet’s main dose - vildagliptin 50mg/metformin 500mg – was released in the market. The introduction of Galvusmet 50/500mg generic had reduced the price of the original by 25.3%, leaving no difference in price between it and the latecomer drugs. In particular, KB Pharma’s salt-modified Vildamet tab 50/500mg, and Korea United Pharm’s Healusmet tab, which received a pricing premium as an innovative pharmaceutical, were listed at ₩310, which is the same price as its original drug. However, Hanmi Pharmaceutical opted to set the price of its salt-modified Vildaglmet tab 50/500mg ₩300, and how this will affect market competition is receiving attention. 빌다글립틴(50mg)/메트포르민(500mg) 동일제제 급여등재 현황 Galvusmet latecomers were able to enter the market earlier after successful patent challenges. Although the original's substance patent was set to expire on March 4th this year, Hanmi and Ahn-gook succeeded in invalidating part of the extended term of the patent and released their generics earlier than the patent expiry date. On this, Novartis has filed an active trial to confirm the scope of its patent against companies other than Hanmi – KB Pharma, Korea United Pharm, Ahn-gook Pharmaceutical, Ahn-gook New Pharm, and Samjin Pharm – on grounds of patent infringement. With patent and drug prices so intricately intertwined, who will be the last to smile in this ₩40 billion market is expected to continue to draw attention.
- Company
- KRPIA BOD meets Oh Chang-hyun, the new head
- by Eo, Yun-Ho Apr 12, 2022 06:05am
- KRPIA BOD will hold its first face-to-face meeting with Oh Chang-hyun, director of the MOHW's insurance pharmaceutical dept. According to related industries, KRPIA Board of Director (BOD) will hold a meeting with Oh Chang-hyun, the new manager, and members of the MOHW's Insurance and Pharmaceutical Affairs on the 15th. The meeting is expected to be accompanied by Oh Dong-wook, CEO of Pfizer Korea, Lee Young-shin, a full-time vice chairman of KRPIA, and some members of the board of directors. Through the discussion meeting, KRPIA BOD is a plan to deliver grievances, policies, and pledges from the perspective of pharmaceutical companies within the agenda of "expanding new drug coverage." As the industry has recently emphasized the need for the introduction of the "post-evaluation of lights" system, it remains to be seen how to proceed with discussions with the changed head of the insurance drug department. KRPIA is also discussing with the 20th Presidential Transition Committee to expand the guarantee of new drugs.
